Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment.

Document Type

Article

Publication Date

8-2018

Identifier

DOI: 10.1016/j.siny.2018.02.006; PMCID: PMC6098727

Abstract

Patent ductus arteriosus (PDA) is a frequent, complex, and difficult to treat clinical syndrome among preterm infants in the neonatal intensive care unit. In addition to known clinical risk factors, there are emerging data about genetic predisposition to PDA in both animal and human models. Clinical response and toxicity from drugs used to treat PDA are highly variable. Developmental and genetic aspects of pharmacokinetics and pharmacodynamics influence exposure and response to pharmacologic therapies. Given the variable efficacy and toxicity of known drug therapies, novel therapeutic targets for PDA treatment offer the promise of precision medicine. This review addresses the known genetic contributions to prolonged ductal patency, variability in response to drug therapy for PDA, and potential novel drug targets for future PDA treatment discovery.

Journal Title

Seminars in fetal & neonatal medicine

Volume

23

Issue

4

First Page

232

Last Page

238

MeSH Keywords

Acetaminophen; Animals; Disease Models, Animal; Ductus Arteriosus, Patent; Genetic Predisposition to Disease; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Infant, Premature; Pharmacogenetics

Keywords

Ductus arteriosus; Genetic predisposition; Infant; Newborn

Link to Full Text
Library Record

Share

COinS